Advertisement

Topics

BRIEF-Achillion announces data from phase 2 trial for combination treatment for Genotype 1 Treatment-Naïve HCV

08:04 EDT 23 Sep 2016 | Reuters

* Announces 100 pct SVR12 In The 6-Week and 8-week cohorts in Janssen'S phase 2 trial evaluating the triple combination treatment regimen including odalasvir, al-335, and simeprevir for genotype 1 treatment-naïve hcv

Original Article: BRIEF-Achillion announces data from phase 2 trial for combination treatment for Genotype 1 Treatment-Naïve HCV

NEXT ARTICLE

More From BioPortfolio on "BRIEF-Achillion announces data from phase 2 trial for combination treatment for Genotype 1 Treatment-Naïve HCV"

Quick Search
Advertisement